Evaluation of Proclarix in the diagnostic work‐up of prostate cancer

Autor: Basil Kaufmann, Sharon Fischer, Alcibiade Athanasiou, Noémie Lautenbach, Anja Wittig, Uwe Bieri, Florian A. Schmid, Franz vonStauffenberg, Thomas Scherer, Daniel Eberli, Michael A. Gorin, Ralph Schiess, Cédric Poyet

Publikováno v: BJUI Compass, Vol 5, Iss 2, Pp 297-303 (2024)

Abstract Objectives The use of multiparametric magnetic resonance imaging (mpMRI) has been widely adopted in the diagnostic work‐up for suspicious prostate cancer (PCa) and is recommended in most current guidelines. However, mpMRI lesions are often

Externí odkaz: https://doaj.org/article/9c1e452d1b7841658ef06caf1736ff8a

Improving the Early Detection of Clinically Significant Prostate Cancer in Men in the Challenging Prostate Imaging-Reporting and Data System 3 Category

Autor: Juan Morote, Miriam Campistol, Marina Triquell, Anna Celma, Lucas Regis, Inés de Torres, Maria E. Semidey, Richard Mast, Anna Santamaria, Jacques Planas, Enrique Trilla

Publikováno v: European Urology Open Science, Vol 37, Iss , Pp 38-44 (2022)

Background: Prostate Imaging-Reporting and Data System (PI-RADS) category 3 is a challenging scenario for detection of clinically significant prostate cancer (csPCa) and some tools can improve the selection of appropriate candidates for prostate biop

Externí odkaz: https://doaj.org/article/cd89f67328fe45c8ab108a9618157aaf

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

New strategy for the identification of prostate cancer: The combination of Proclarix and the prostate health index

Autor: Daniela Terracciano, Evelina La Civita, Alcibiade Athanasiou, Antonietta Liotti, Mariano Fiorenza, Michele Cennamo, Felice Crocetto, Pierre Tennstedt, Ralph Schiess, Alexander Haese, Matteo Ferro, Thomas Steuber

Publikováno v: The ProstateREFERENCES. 82(15)

Prostate health index (PHI) and, more recently, Proclarix have been proposed as serum biomarkers for prostate cancer (PCa). In this study, we aimed to evaluate Proclarix and PHI for predicting clinically significant prostate cancer (csPCa).Proclarix

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4cf27d62cea846d6b13d7a06d864f03
https://pubmed.ncbi.nlm.nih.gov/35971798

Improving the Early Detection of Clinically Significant Prostate Cancer in Men in the Challenging Prostate Imaging-Reporting and Data System 3 Category

Autor: Juan Morote, Miriam Campistol, Marina Triquell, Anna Celma, Lucas Regis, Inés de Torres, Maria E. Semidey, Richard Mast, Anna Santamaria, Jacques Planas, Enrique Trilla

Publikováno v: Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
European Urology Open Science, Vol 37, Iss, Pp 38-44 (2022)
Scientia

The efficacy of tools for selection of candidates for prostate biopsy after multiparametric magnetic resonance imaging (MRI) varies across Prostate Imaging-Reporting and Data System (PI-RADS) categories. The new Proclarix test performs better than pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3798e3e7de869c5d68737ebce7a4ecb1
https://pubmed.ncbi.nlm.nih.gov/35243388